Drug intelligence / Profile preview

11-dehydrosinulariolide

Development stage
Preclinical
Modality
Small Molecules
Administration
Intraperitoneal
01

Overview

11-Dehydrosinulariolide is a bioactive cembranolide diterpene isolated from the cultured soft coral *Sinularia flexibilis*. It has demonstrated significant anti-tumor activity in preclinical models, particularly against small cell lung cancer (SCLC), oral squamous cell carcinoma, and melanoma. The compound exerts its effects by inducing G2/M phase cell cycle arrest and triggering apoptosis through multiple pathways. Key mechanisms include the activation of the DNA damage response via the ATM/Chk2 pathway, upregulation of p53 and Bax, and activation of caspases-3 and -7. Additionally, it promotes the accumulation of the tumor suppressor PTEN, which subsequently inhibits the Akt signaling pathway, further suppressing tumor cell proliferation and survival.

Other names
11-dehydrosinulariolide
02

Targets

ATM (Ataxia telangiectasia mutated protein)BAX (Apoptosis regulator BAX)CASP3 (Caspase-3)CASP7 (Caspase-7)CHEK2 (Checkpoint kinase 2)PTEN (Phosphatase and tensin homolog deleted on chromosome ten)TP53 (Cellular Tumor Antigen p53 R175H)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)

Beyond the preview

Go deeper on 11-dehydrosinulariolide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 11-dehydrosinulariolide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call